EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting MLL1 / WDR5 ‐Mediated Epigenetic Regulation Mitigates Peritoneal Fibrosis by Reducing p16 INK4a

Daisuke Hara, Kensuke Sasaki iD, Shigehiro Doi, Takeshi Ike, Kazuya Maeda, Maria Yoshida, Akira Takahashi, Yosuke Osaki, Naoki Ishiuchi, Yujiro Maeoka, Toshiki Doi, Takuto Chiba und 2 weitere

The FASEB Journal · 2025

DOI: 10.1096/fj.202402382r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Daisuke Hara und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase Inhibitor p16, Myeloid-Lymphoid Leukemia Protein, Epigenesis, Genetic, Histone-Lysine N-Methyltransferase. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ryokufukai Foundation, HHS|NIH|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), MEXT|Japan Society for the Promotion of Science (JSPS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peritoneal fibrosis poses a significant challenge to the long‐term efficacy of peritoneal dialysis (PD), with emerging evidence highlighting the role of cellular senescence in its pathogenesis. p16 INK4a is a cell cycle regulator that has been implicated in cellular senescence. Mixed‐lineage leukemia 1 (MLL1) forms a complex with WD‐40 repeat protein 5 (WDR5) and exhibits histone H3K4 methyltransferase activity. We have previously shown that inhibition of the MLL1/WDR5 complex reduces p16 INK4a expression and attenuates renal senescence after injury in mice. This study aimed to investigate whether inhibiting MLL1/WDR5 attenuates peritoneal senescence, inflammation, and fibrosis in both human samples and in mice with methylglyoxal (MGO)‐induced peritoneal fibrosis (MGO‐injected mice), while also exploring the associated underlying mechanisms. MLL1/WDR5, histone 3 lysine 4 trimethylation (H3K4me3), and p16 INK4a expression were elevated in TGF‐β1‐stimulated human peritoneal mesothelial cells (HPMCs), non‐adherent cells obtained from patients undergoing PD, and the submesothelial compact zones of MGO‐injected mice. Notably, p16 INK4a expression in these cells was positively correlated with the dialysate/plasma creatinine ratio. Treatment with the MLL1/WDR5 protein–protein interaction inhibitors MM‐102 and OICR‐9429 reduced H3K4me3 levels and p16 INK4a expression, suppressing fibrosis in HPMCs as well as peritoneal fibrosis and inflammation in MGO‐injected mice. These inhibitors also improved peritoneal function in MGO‐injected mice. Additionally, we demonstrated that MLL1/WDR5‐induced H3K4me3 directly regulates p16 INK4a gene transcription, and that inhibiting MLL1/WDR5 reduces H3K4me3, thereby suppressing p16 INK4a gene transcription. These findings suggest that targeting MLL1/WDR5 activation alleviates peritoneal senescence, inflammation, and fibrosis, highlighting its potential as a promising therapeutic strategy for peritoneal fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase Inhibitor p16Myeloid-Lymphoid Leukemia ProteinEpigenesis, GeneticHistone-Lysine N-MethyltransferasePeritoneal FibrosisIntracellular Signaling Peptides and ProteinsAnimalsHumansMiceMaleMice, Inbred C57BLFemaleCellular SenescencePyruvaldehydeHistones

Stichwörter der Autor:innen

MLL1/WDR5epigeneticsperitoneal dialysisperitoneal fibrosisperitoneal inflammationsenescence

Substanzen

Cyclin-Dependent Kinase Inhibitor p16Myeloid-Lymphoid Leukemia ProteinHistone-Lysine N-MethyltransferaseKMT2A protein, humanWDR5 protein, humanIntracellular Signaling Peptides and ProteinsWdr5 protein, mouseCDKN2A protein, humanKmt2a protein, mousePyruvaldehyde

Autor:innen und Institutionen

  • Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.
  • Division of Nephrology, Ichiyokai Harada Hospital, Hiroshima, Japan.
  • Division of Nephrology, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Kensuke Sasaki

Förderung

  • Ryokufukai Foundation
  • HHS|NIH|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • MEXT|Japan Society for the Promotion of Science (JSPS)
  • NIDDK NIH HHS
  • Japanese Association of Dialysis Physicians (JAPD)
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Japan Society for the Promotion of Science

Zitieren

APA

Hara, D., Sasaki, K., Doi, S., Ike, T., Maeda, K., Yoshida, M., Takahashi, A., Osaki, Y., Ishiuchi, N., Maeoka, Y., Doi, T., Chiba, T., Nakashima, A., & Masaki, T. (2025). Targeting MLL1 / WDR5 ‐Mediated Epigenetic Regulation Mitigates Peritoneal Fibrosis by Reducing p16 INK4a. The FASEB Journal. https://doi.org/10.1096/fj.202402382r

Vancouver

Hara D, Sasaki K, Doi S, Ike T, Maeda K, Yoshida M, et al. Targeting MLL1 / WDR5 ‐Mediated Epigenetic Regulation Mitigates Peritoneal Fibrosis by Reducing p16 INK4a. The FASEB Journal. 2025. doi:10.1096/fj.202402382r

BibTeX
@article{Hara2025,
  author = {Hara, Daisuke and Sasaki, Kensuke and Doi, Shigehiro and Ike, Takeshi and Maeda, Kazuya and Yoshida, Maria and Takahashi, Akira and Osaki, Yosuke and Ishiuchi, Naoki and Maeoka, Yujiro and Doi, Toshiki and Chiba, Takuto and Nakashima, Ayumu and Masaki, Takao},
  title = {Targeting MLL1 / WDR5 ‐Mediated Epigenetic Regulation Mitigates Peritoneal Fibrosis by Reducing p16 INK4a},
  journal = {The FASEB Journal},
  year = {2025},
  doi = {10.1096/fj.202402382r}
}
Kostenlos starten →